Bundled Webinars
Collapse 2016 World Health Organization (WHO) Updates in Hematologic Malignancies (+AMP Certificate)

This AMP certificate program contains 5 hours of lecture content, the lecture slides, a key reference sheet, a post-course exam, and an AMP Certificate of Completion. It does not include CME/CMLE or SAM. If you would like to obtain CE credit for this program, see the table below to purchase CME/CMLE or SAM.


Description:

Since the publication of the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues in 2008, there have been significant advances in our knowledge of the biology and genetics of hematopoietic malignancies resulting in improved diagnostic and prognostic criteria, disease classification and therapeutic strategies. The 2016 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues incorporates these advances with revisions to current entities and addition of provisional entities. This AMP certificate program will cover the major changes made in the 2016 WHO revision. Participants will learn from experts in the field covering the following topics: B lymphoid neoplasms, Peripheral T cell lymphomas, Acute Leukemias, Myeloproliferative Neoplasms, Myelodysplastic syndromes and Myelodysplastic/myeloproliferative neoplasms. An update on the clinicopathologic features and classification of hematologic malignancies will be presented providing participants with skills and knowledge to accurately diagnose and subclassify hematologic malignances according to the revised 2016 WHO criteria.

Target Audience: Practicing pathologists, oncologists, medical trainees and other healthcare professionals in the U.S. and abroad.

This certificate program was planned and coordinated by the Content Directors:

  • Jennifer Dunlap, MD, Oregon Health & Science University, Portland, OR
  • Mark D, Ewalt, MD, University of Colorado, Denver, CO

and supported by the Training & Education Committee (Cecilia C.S. Yeung, MD, Chair) 

Duration: 5 hours

Certificate Program Topics (for details about each topic, click on the “Topics” tab at the top of the page)

  • B-Lymphoid Neoplasms (Eric D. Hsi, MD)
  • Nodal Peripheral T-cell Lymphomas (Stefano A. Pileri, MD)
  • Acute Leukemias (Daniel A. Arber, MD)
  • Myeloidproliferative Neoplasms (Tracy I. George, MD)
  • MDS and MDS/MPN (Robert Hasserjian, MD)

 

Click the "Add to Basket" button on the right to purchase this entire certificate program. Individual webinars are also available for purchase but does not include the key reference sheet, the post-course exam, or the AMP Certificate of Completion. 

 

The content for this certificate program was made in collaboration with Association for Molecular Pathology (AMP) and Society for Hematopathology (SH)


CME/CMLE or SAMs: If you wish to obtain CME/CMLE or SAMs, click on the appropriate link to purchase the collection +CME/CMLE or +SAM. These also contain the AMP Certificate of Completion

Credit Type

Number of Credit Hours Available

Click on link to purchase:

CME/CMLE

Up to 5.0

Purchase collection + CME/CMLE + AMP certificate

SAM

Up to 5.0

Purchase collection + SAM + AMP certificate

Continuing education credit must be purchase and claimed by January 18, 2021

 

You might also be interested in:

 

Note: Members of AMP can access this at a deep discount. Join the AMP Family!

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Formats Available: WHO AMP Certificate
Original Course Date: May 31, 2018

Approved Credit:
  • AMP: 5.00 hours Molecular Pathology Content

  • MORE INFOMORE INFO 2016 World Health Organization (WHO) Updates in Hematologic Malignancies (+AMP Certificate)
    Collapse Advancing Patient Care in NSCLC: Breaking Down Barriers (CE Available)

    This webinar series includes the presentations and the audience QAs recorded from the live broadcast and the associated slide handouts. If you would like continuing education credit for the webinars, click on the links in the table below to access the webinars + CME/CMLE or webinars + SAM


    Speakers:

    Neal Lindeman, MD Eric H. Bernicker, MD Dara Aisner, MD, PhD
    Lynette M. Sholl, MD Sinchita Roy-Chowdhuri, MD, PhD Christopher R. Gilbert, DO, MS, FCCP

     

    Series Description: Over the past 10 years, understanding of oncogenic signal transduction pathways has fundamentally altered the treatment paradigm for advanced NSCLC, leading to personalized treatment. As a result, diagnosing and treating NSCLC has evolved from a relatively simple “one-size-fits-all” approach to an extremely complex algorithm that requires personalized treatment plans. 

    This free online learning experience is aimed at breaking down barriers to testing and treatment in Non-Small Cell Lung Cancer (NSCLC). Hear from world-renowned experts and explore best practices in test ordering, sample collection, and test interpretation with the goal of improving patient care.

    Webinars include: (Click "Topic" tab for descriptions)

    • Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision
      Speaker: Neal Lindeman 
      Recorded: May 29, 2018
    • Best Practices in NSCLC Small Specimen Collection for Clinicians 
      Speaker: Eric Bernicker 
      Recorded: June 20, 2018
    • Best Practices in Small Specimen Management for Laboratory Professionals
      Speaker: Dara Aisner
      Recorded: August 16, 2018
    • Liquid Biopsies – Promises and Pitfalls 
      Speaker: Lynette Sholl
      Recorded: October 9, 2018
    • Best Practices in Test Ordering 
      Speakers: Sinchita Roy-Chowdhuri and Christopher R. Gilbert
      Recorded: December 13, 2018

    Duration: 5 hr

    Level of Instruction: Basic

    • Add the entire series into your classroom by clicking "Add to Basket" button located on the right.
    • Add individual webinars into your classroom by clicking on the "Purchase Individual Topics" button on the right. Select the particular webinar(s) that you would like and proceed through checkout.

     

    This webinar is a five-part series aimed at breaking down barriers to NSCLC testing and treatment. If you'd like more information about the series go here.

    Supported by an educational grant provided by AstraZeneca


    Click on the links below to access continuing education credit.

    Credit Type Number of Credit Hours Click on link to purchase:
    CME/CMLE Maximum 5.0

    Webinar + CME/CMLE
    (Free for all)

    SAM Maximum 5.0

    Webinar + SAM
    (Free for all)

    Continuing Education Credit must be purchased and claimed by May 29, 2019

    You may also be interested in:

     

    Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

    All sales are final. No refunds will be issued.

    No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

    Formats Available: NSCLC Series 1
    Original Course Date: May 29, 2018
    MORE INFOMORE INFO Advancing Patient Care in NSCLC: Breaking Down Barriers (CE Available)
    Collapse Circulating Tumor DNA Testing: Advances, Challenges, and Applications (+AMP Certificate)

    This AMP certificate program contains 5 hours of lecture content, the associated pdf slides of the lectures, a post-course exam, and an AMP Certificate of Completion. It does not include CME/CMLE or SAM.


    Circulating tumor DNA has shown much promise as a minimally invasive test that could allow for disease detection, identification of targetable variants, and monitoring of tumor response. This AMP certificate program, featuring expert speakers in the field, will: define circulating tumor DNA, explain technical challenges, describe approaches for assay design and validation, highlight clinical applications of testing, and will review selected new published studies and guidelines. Participants can expect, upon completion of this certificate program, to be familiar with the current state of circulating tumor DNA testing for personalized medicine. 


    Target Audience: Practicing pathologists, oncologists, medical trainees and other healthcare professionals in the U.S. and abroad.

    This certificate program was planned and coordinated by the Content Directors:

    • Rashmi Goswami, MD, PhD, Sunnybrook Health Sciences Centre, University of Toronto
    • Susan Hsiao, MD, PhD Columbia University Medical Center

    and supported by the Training & Education Committee (Cecilia C.S. Yeung, MD, Chair) 

    Duration: 5 hours


    There is no CME/CMLE or SAMs available for this certificate program.


    You might also be interested in:

     

    Note: Members of AMP can access this webinar for a discount. Join the AMP Family!

    All sales are final. No refunds will be issued.

    No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

     

    Formats Available: AMP Certificate ctDNA
    Original Course Date: November 26, 2018

    Approved Credit:
  • AMP: 5.00 hours Molecular Pathology Content

  • MORE INFOMORE INFO Circulating Tumor DNA Testing: Advances, Challenges, and Applications (+AMP Certificate)
    Collapse NGS 101: Introduction to the Fundamentals of Next-Generation Sequencing

    Description:

    Looking to add Next-Generation Sequencing (NGS) to your lab? Familiar with NGS but in need of a refresher? This 5-part series on the fundamentals of NGS is for you! Recorded in 2014 and 2015 “NGS 101” is a comprehensive primer on implementing and running NGS in your lab. To see details on the individual parts of this series, click “Topics."

    Duration:  5 hrs

    This content is now FREE for all, but continuing education credit is not available.

    You can purchase individual sessions or purchase all the chapters.

    • To purchase the entire series, click the "Add to Cart" button located on the right.
    • To purchase individual talks, click on the "Purchase Individual Topics" button on the right, and select the particular session(s) that you would like to purchase.

    If you have questions, please email AMPeducation@amp.org

    Reviewed: March, 2018

    • This course provides a good overview of basic principles of NGS. However, technologies, platforms, and techniques discussed in the talks are always evolving. Look for an updated NGS course from AMP in the future.

     

    All sales are final. No refunds will be issued.

     

    Formats Available: Streaming
    Original Course Date: December 31, 2015
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO NGS 101: Introduction to the Fundamentals of Next-Generation Sequencing
    Collapse Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care (CE Available)

    This webinar series includes the presentations and the audience QAs recorded from the live broadcast and the associated slide handouts. If you would like continuing education credit for the webinars, click on the links in the table below to access the webinars + CME/CMLE or webinars + SAM


    Speakers: 

    Lauren Ritterhouse 
    MD, PhD

    Jonathan Nowak
    MD, PhD

    Ahmet Zehir
    PhD

    Series Description: Examining the mutational profile of tumors has become much easier because of the advances and accessibility of next-generation sequencing techniques. Analyzing the genetic signatures of tumors might identify patients who have higher chances of responding to checkpoint inhibition. Various studies have shown how the mutational burden correlates with greater efficacy of anti-PD-L1/PD-1 therapies, however tumor mutational burden (TMB) testing methodology and classification have not yet been standardized in clinical practice. This educational webinar series will provide information regarding current best practices in TMB testing, interpretation, and reporting.

    Webinars include: (Click "Topic" tab for descriptions)

    • Tumor Mutational Burden: Clinical and Diagnostic Utilization in Oncology 
      Speaker: Lauren Ritterhouse
      Recorded: June 27, 2018
    • Tumor Mutational Burden: Best Practices to Address Clinical and Technical Challenges 
      Speaker: Jonathan Nowak
      Recorded: August 28, 2018
    • Tumor Mutational Burden: Result Reporting and Application to Improve Patient Care
      Speaker: Ahmet Zehir
      Recorded: September 26, 2018

     

    Duration: 3 hr

    Level of Instruction: Basic

    • To access the entire series, click the "Add to Basket" button located on the right.
    • To access individual webinars, click on the "Purchase Individual Topics" button on the right, and select the particular webinar(s) that you would like to access.

     

    This is a three-part series exploring how measuring tumor mutational burden can improve patient care. If you'd like more information about the series go here.

    This program has been supported through an educational grant from Bristol-Myers Squibb.


    Click on the links below to access continuing education credit.

    Credit Type Number of Credit Hours Click on link to purchase:
    CME/CMLE Maximum 3.0

    Webinar + CME/CMLE
    (Free for all)

    SAM Maximum 3.0

    Webinar + SAM
    (Free for all)

    Continuing Education Credit must be purchased and claimed by June 27, 2019

    You may also be interested in:

    Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!

    All sales are final. No refunds will be issued.

    No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

    Formats Available: TMB Series 1
    Original Course Date: September 26, 2018
    MORE INFOMORE INFO Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care (CE Available)